What drove the FEED stock spike today?

ENvue’s U-Deliver distribution agreement for over-the-counter ENFit syringes was the primary catalyst, expanding non-acute channel access and sparking heavy trading volume in the United States markets.

What is the Meyka AI price forecast for FEED stock?

Meyka AI's forecast model projects a 12-month base target of $3.50 versus the current $2.30, implying an upside of 52.17%. Forecasts are model projections and not guarantees.

How does ENvue’s financial health affect FEED stock?

ENvue has negative EPS and negative operating cash flow per share, a current ratio of 0.86, and low debt. These factors increase execution risk despite strong product and distribution progress.

Where can I read the original company release on the U-Deliver deal?

ENvue’s announcement is available via the GlobeNewswire release posted on Seeking Alpha [source](https://seekingalpha.com/pr/20379259-envue-medical-signs-strategic-partnership-agreement-with-u-deliver-for-u-s-distribution-of).

US Stocks

FEED stock ENvue Medical (NASDAQ) $2.30 Jan 29 2026: U‑Deliver expands OTC reach

ByDanny Kontos January 30, 2026January 30, 2026

FEED stock opened market attention after ENvue Medical, Inc. (FEED) traded at $2.30 on NASDAQ on 29 Jan 2026, with the market closed for the session. Volume spiked to 273,465,900.00 shares, making FEED one of the most active names today in the United States. The rally followed a distribution deal with U-Deliver for ENvue’s over-the-counter ENFit syringes, a commercial step that connects product launches to measurable trading activity. We examine the news, key financial metrics, technicals, and the Meyka AI outlook for FEED stock.